Biochemical amenability in Fabry patients under chaperone therapy - how and when to test?

Malte Lenders, Elise Raphaela Menke, Eva Brand

Journal: *BioDrugs*

Internal Medicine D (Nephrology, Hypertension and Rheumatology), and Interdisciplinary Fabry Center (IFAZ), University Hospital Muenster, Muenster, Germany

Corresponding author: PD Dr. rer. nat. habil. Malte Lenders
University Hospital Muenster
Internal Medicine D
Nephrology, Hypertension and Rheumatology
Interdisciplinary Fabry Center (IFAZ)
Albert-Schweitzer-Campus 1
D-48149 Muenster
phone: +49(251) 83-48104
fax: +49(251) 83-47545
email: Malte.Lenders@ukmuenster.de



Supplemental Figure 1: Serum-mediated inhibition measurements (A) and AGAL activity in DBS (B) in samples before and after 24 hours after migalastat intake. The red dotted line at 2.8 µmol/l/h marks the lower limit of quantification. The red dotted line at 15.3 µmol/l/h marks the reference activity of normal values. AGAL: α-galactosidase A. *p<0.05, ***p<0.0001.



Supplemental Figure 2: DBS-based enzymatic AGAL activities at migalastat-naïve baselines and during treatment. A) Blood drawings for DBS were drawn <24 hours after migalastat intake (n=10 patients). **B)** Blood drawings for DBS were drawn ≥24 hours after migalastat intake (n=7 patients). The red dotted line at 2.8 µmol/l/h marks the lower limit of quantification (LOQ).The green dotted line at 15.3 µmol/l/h marks the reference activity of normal values (Ref). AGAL: α-galactosidase A, DBS: dried blood spot.